Trial Profile
Post marketing surveillance study of tocilizumab in patients systemic-onset juvenile idiopathic arthritis.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 11 Dec 2015
Price :
$35
*
At a glance
- Drugs Tocilizumab (Primary)
- Indications Juvenile rheumatoid arthritis
- Focus Therapeutic Use
- Sponsors Chugai Pharmaceutical
- 07 Dec 2015 Results published in the Annals of the Rheumatic Diseases
- 04 Dec 2015 New trial record